Physician profile
Mohammad Riaz
NPI 1619947421
$5,030.33
in general payments reported to CMS, 2019-2025
60 companies · $98.05 in 2025
The $98.05 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,581 · 2020: $983 · 2021: $1,303 · 2022: $514 · 2023: $392 · 2024: $159 · 2025: $98.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $649.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $662.22 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $432.54 | 2019-2023 | Keytruda |
| Celgene Corporation | $262.22 | 2019-2024 | Pomalyst, Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $249.16 | 2019-2023 | Opdivo |
| Lilly USA, LLC | $224.38 | 2019-2025 | Verzenio, Jaypirca |
| Janssen Biotech, INC. | $216.90 | 2019-2025 | Tremfya, Rybrevant |
| Taiho Oncology, INC. | $213.26 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $151.93 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $151.81 | 2019-2022 | |
| Genentech USA, INC. | $149.55 | 2019-2023 | Tecentriq, Polivy |
| Tersera Therapeutics LLC | $140.67 | 2020-2021 | |
| Verastem, INC. | $134.56 | 2019 | |
| Genzyme Corporation | $98.45 | 2019-2021 | |
| Daiichi Sankyo INC. | $95.73 | 2019-2024 | Enhertu |
| Mylan Institutional INC. | $94.92 | 2019-2022 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Riaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.